Yesterday, Roche announced a halt to the Phase 3 CREAD 1 and CREAD 2 trials of the anti-amyloid antibody crenezumab. According to a company press release, an interim analysis found the trial was ...
SLINGERLANDS, N.Y., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, has secured a contract with ...
Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results